Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China
Crossref DOI link: https://doi.org/10.1371/journal.pone.0328730
Published Online: 2025-07-24
Update policy: https://doi.org/10.1371/journal.pone.corrections_policy
Kang, Shuo https://orcid.org/0000-0002-8690-4259
Zhao, Shan
Wang, Xiaohui
Pan, Zhenhua https://orcid.org/0009-0000-3276-728X
Version of Record valid from 2025-07-24
